Rare Diseases Genetic Disorders An Overview of Familial Dysautonomia Long-term Care of a Chronic Disease By Ruth Jessen Hickman, MD Ruth Jessen Hickman, MD Facebook LinkedIn Ruth Jessen Hickman, MD, is a freelance medical and health writer and published book author. Learn about our editorial process Updated on July 10, 2022 Medically reviewed by Lyndsey Garbi, MD Medically reviewed by Lyndsey Garbi, MD LinkedIn Lyndsey Garbi, MD, is a pediatrician who is double board-certified in pediatrics and neonatology. Learn about our Medical Expert Board Print Table of Contents View All Table of Contents Symptoms Causes Diagnosis Treatment Coping Familial dysautonomia (FD) is a serious and rare genetic condition that affects the survival of specific nerve cells, primarily parts of the autonomic nervous system and sensory neurons. This affects the body’s control of involuntary actions, such as breathing, digesting, making tears, salivating, and regulating blood pressure and temperature. Reduced sensitivity to pain and temperature is another major problem. The condition was first described in 1949 by two researchers, Riley and Day, and it is sometimes called Riley-Day syndrome. Type III hereditary sensory and autonomic neuropathy (HSAN type III) also refers to the same medical problem. The condition occurs primarily in people of Ashkenazi Jewish ancestry. In this group, it affects about one person in 3,700. Judith Haeusler / Getty Images Symptoms Familial dysautonomia is a debilitating disease that can cause many different symptoms. These appear early in infancy, and might first show up as low muscle tone, absence of tears, and difficulty maintaining body temperature. Additional symptoms may appear, such as: Difficulty swallowing Poor growth Frequent lung infections Excessive saliva Episodes of vomiting Delays in reaching physical milestones Gastroesophageal reflux disease Bedwetting Abnormal heart rhythms Dry eyes, which can lead to corneal abrasions Other eye problems, like strabismus Decreased taste sensation Breathing issues during sleep Abnormal curving of the spine (scoliosis) Poor balance and broad gait that worsens over time Poor regulation of blood pressure is also a common problem. This might cause orthostatic hypotension, a lowering of blood pressure when standing, which might trigger dizziness or fainting. The periodic increases in blood pressure also tend to cause kidney problems over the long-term. Insensitivity to pain and temperature is another problem. This can contribute to injury, for example, if an affected person doesn’t notice to remove their hand from a very hot object. Many people with FD have normal intelligence, but some people have learning issues such as attention deficit problems. About 40% of people with FD experience periodic worsening of certain symptoms, called “autonomic crises.” During one of these crises, a person might experience symptoms like excessive sweating, reddish blotting of the skin, rapid changes in blood pressure and heart rate, and vomiting episodes. People with FD also have a decreased life expectancy, on average. Some people with the condition die from complications from pneumonia. Others suffer from sudden unexplained death during sleep or from other disease complications. Causes The symptoms of familial dysautonomia make sense when you learn about the part of the body that’s affected by the disease. The disease seems to affect mostly neurons. The autonomic neurons of the body seem particularly prone to problems. These are the neurons that help regulate the autonomic nervous system. This system helps regulate many automatic functions of your body, such as breathing, blood pressure, sweating, salivating, regulating temperature, and digesting. That’s why these parts of the body seem particularly prone to problems. The disease also affects some sensory neurons, which is why sensations of temperature and pain are impaired. Some of the other problems of FD result from complications of these issues. For example, people with FD suffer from periods of very high blood pressure. This, in turn, can damage the kidneys over the long-term. Genetic Mutation There are other medical issues that can cause problems with the autonomic nervous system. But in familial dysautonomia, these problems are caused by mutations in a single gene. Specifically, mutations in a gene called “ELP1” (also known as IKAP) cause the disease. This gene makes a protein whose function isn’t completely understood. However, we do know that it seems to be important in the proper development of the nervous system. When a person has a genetic mutation in ELP1, the body can’t make enough of the functional protein where it’s needed. This is particularly true for certain cells in the nervous system. This is what causes the problems with parts of the nervous system that lead to symptoms. FD is one of a group of related disorders, the hereditary sensory and autonomic neuropathies (HSANs). These disorders are all inherited genetically, and they all can affect both sensory and autonomic neurons. However, they have slightly different genetic causes, and thus have somewhat different (though overlapping) symptoms. All the other disorders in this group, including FD, cause some sensory and autonomic symptoms. How the Disease is Inherited Familial dysautonomia is an autosomal recessive genetic condition. That means that a person with FD received an affected gene from both of their parents. People who carry only one copy of the gene (called carriers) don’t have any symptoms. If a couple has had one child with FD, there is a 25% chance that another child of theirs would also have the disease. If you know that there is FD in your family, it is often helpful to work with a genetic counselor. For couples of Ashkenazi Jewish descent, the gene causing FD is often included as part of a panel of genes that can be tested prior to conception. Prenatal testing and preimplantation genetic testing are possibilities for couples at risk of having a child with FD. Diagnosis The diagnostic process begins with a history and a thorough medical exam. Family history is also important, though an infant may be the first person known in a family to have the disease. Clinicians try to get as much information to evaluate the possible diagnoses. This can even begin in-utero with an accuracy greater than 99%. Since prenatal screening for the familial dysautonomia gene became available in 2001, the rate of babies born with the disease has decreased in the US. FD is a rare condition, and there are many other problems that can cause some of the symptoms of FD. For example, other neurological syndromes and or other hereditary and sensory neuropathies might cause some similar problems. It’s important to rule out these other possible causes. Taken together, certain clues can help a practitioner make the correct diagnosis. These include the presence of the following: Low muscle tone in infancyAbsent or decreased deep tendon reflexesSmooth, pale appearing tongueAbsence of tearsAshkenazi Jewish genetic background Testing is also an important part of the diagnostic process. A wide array of tests will be done initially as clinicians try to get an idea of what is going on. These might include general tests, like blood tests and a complete metabolic panel. Other tests to assess the nervous system might be important, like brain imaging tests or electroencephalography. Initial tests might vary depending on how symptoms first appear. There are a couple of specific tests that can help diagnosis FD if a clinician suspects it. One is the response to a subcutaneous injection of histamine. People with FD show a very specific skin response (called “lack of axon flare”). Another test uses eye drops of the medication methacholine (which affects the autonomic nervous system). The pupil of someone with FD will shrink in size dramatically after these drops. Genetic testing is usually needed to confirm the diagnosis. Blood tests can be sent to a laboratory, which will check for the specific genetic mutation known to cause FD. It is often helpful to work with a clinician with experience in rare genetic diseases when trying to find the exact diagnosis. Treatment There is currently no treatment approved by the U.S. Food and Drug Administration (FDA) that can directly address the disease and its progression. However, there are many interventions that can help address the disease’s problems and help prevent complications. Some of these are only needed temporarily, such as to address a crisis of increased blood pressure or a pneumonia infection. Others are needed more long-term. These treatments will be specifically tailored to the individual’s needs. Some possible treatments might include: Gastronomy tube (g-tube) to maintain nutrition Medications for gastroesophageal reflux disease (like omeprazole) IV fluids for vomiting crises Chest physiotherapy, to help prevent lung infections Antibiotics for lung infection Pacemaker for fainting or orthostatic hypotension Elastic stockings and leg maneuvers to help with orthostatic hypotension Drugs like diazepam to treat hypertensive episodes and vomiting crises Drugs like midodrine, to treat orthostatic hypotension Drugs like ACE-inhibitors, for kidney disease Drugs like glycopyrrolate, to decrease saliva production Artificial tears for protection of the cornea Surgery or orthopedic devices for scoliosis Positive airway pressure (CPAP or BiPAP) for disordered breathing during sleep Treatments Under Development Researchers are working to find treatments that might directly treat the disease itself. One promising treatment is a compound called phosphatidylserine, which is approved by the FDA as an over-the-counter food supplement. Some scientific research suggests that this food supplement may slow the course of the disease by increasing levels of ELP1. Currently, clinical trials of the compound are ongoing that will provide more information about its safety and effectiveness. Clinical trials are also ongoing for another potential treatment called “kinetin.” Potentially, it may also increase the levels of functioning ELP1. Hopefully, FDA approval of one or more of these investigational treatments will improve the lives of people with FD. It remains to be seen whether these treatments might help slow or reverse the disease process. Other potential treatments are also under development. Exploring Clinical Trials Talk to your healthcare provider if you might be interested in learning more about clinical trials for FD. You can also check the US clinical trials database. There are risks and potential benefits with any clinical trial, but it never hurts to learn more about whether it might be an option in your situation. Monitoring Regular monitoring is also an important part of managing the disease. This is important because certain symptoms of the disease can worsen over time. For example, people with FD may need to receive:Regular assessments for chronic respiratory diseaseRegular monitoring of blood pressure and cardiovascular problemsRegular eye examsScreening for disordered breathing during sleepRegular exams of the spine Coping Certain situations can temporarily worsen certain symptoms of FD. When possible, these situations should be avoided in people with the condition. These might include: Being out in hot and humid weatherHaving an overly full bladderTaking long car ridesExperiencing emotional stress or pain It’s also important for caregivers to take care of themselves. When dealing with a chronic and severe condition like familial dysautonomia, it’s important to reach out to others. As a family, it will take major adjustments to accommodate your child’s best care. But it is easier than ever before to network with other families who have experience with the disease. The Familial Dysautonomia Foundation provides many resources for support. A Word From Verywell It can be devastating to learn that your child has a major medical condition like familial dysautonomia. Give yourself time to take in the news. Fortunately, newer and better treatments may be on the way. With time, education, and the support of your healthcare team, you will continue to learn about the best way to advocate for your loved one. 14 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Familial dysautonomia. Genetics Home Reference. US National Library of Medicine. January 2020. Gadoth N. Clinical diagnostic pearls in Familial Dysautonomia. J Rare Dis Res Treat. 2018;3(2):25-28. Familial Dysautonomia. Harvard Medical School. December 2018. Portnoy S, Maayan C, Tsenter J, et al. Characteristics of ataxic gait in familial dysautonomia patients. PLoS ONE. 2018;13(4):e0196599. doi:10.1371/journal.pone.0196599 Familial dysautonomia. US National Library of Medicine. October 2018. Palma JA, Norcliffe-kaufmann L, Fuente-mora C, Percival L, Mendoza-santiesteban C, Kaufmann H. Current treatments in familial dysautonomia. Expert Opin Pharmacother. 2014;15(18):2653-71. doi:10.1517/14656566.2014.970530 Shohat M, Hubshman MW. Familial dysautonomia in Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. University of Washington, Seattle. December 2014. Screening for Familial Dysautonomia. NYU Langone. Kaur J, Pania S. Floppy Infant Syndrome: Overview. Int J Physiother Res 2016, Vol 4(3):1554-63. doi:10.16965/ijpr.2016.134 Boone N, Bergon A, Loriod B, et al. Genome-wide analysis of familial dysautonomia and kinetin target genes with patient olfactory ecto-mesenchymal stem cells. Hum Mutat. 2012;33(3):530-40. doi:10.1002/humu.22010 Kazachkov M, Palma JA, Norcliffe-kaufmann L, et al. Respiratory care in familial dysautonomia: Systematic review and expert consensus recommendations. Respir Med. 2018;141:37-46. doi:10.1016/j.rmed.2018.06.017 Keren H, Donyo M, Zeevi D, Maayan C, Pupko T, Ast G. Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells. PLoS ONE. 2010;5(12):e15884. doi:10.1371/journal.pone.0015884 The Safety and Tolerability of Kinetin, in Patients With Familial Dysautonomia. ClinicalTrials.gov. June 2019. Mendoza-santiesteban CE, Palma JA, Hedges TR, et al. Pathological Confirmation of Optic Neuropathy in Familial Dysautonomia. J Neuropathol Exp Neurol. 2017;76(3):238-244. doi:10.1093/jnen/nlw118 Additional Reading Familial Dysautonomia. Genetics Home Reference. NIH. Reviewed August 2013. Dietrich P, Dragatsis I. Familial dysautonomia: mechanisms and models. Genet Mol Biol. 2016;39(4):497–514. doi:10.1590/1678-4685-GMB-2015-0335 Naftelberg S, Abramovitch Z, Gluska S, et al. Phosphatidylserine ameliorates neurodegenerative symptoms and enhances axonal transport in a mouse model of familial dysautonomia. PLoS Genet. 2016;12(12):e1006486. doi:10.1371/journal.pgen.1006486 Palma JA, Norcliffe-Kaufmann L, Fuente-Mora C, et al. Current treatments in familial dysautonomia. Expert Opin Pharmacother. 2014;15(18):2653–2671. doi:10.1517/14656566.2014.970530 Shohat M, Weisz Hubshman M. Familial Dysautonomia. 2003 Jan 21 [Updated 2014 Dec 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. By Ruth Jessen Hickman, MD Ruth Jessen Hickman, MD, is a freelance medical and health writer and published book author. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit